Literature DB >> 11012569

Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction.

P Maison1, P Démolis, J Young, G Schaison, J F Giudicelli, P Chanson.   

Abstract

BACKGROUND AND OBJECTIVES: Hypertension is found in one-third of acromegalic patients. An heterogenous distribution of cardiac output has been recently demonstrated in acromegalic patients with an increased blood flow at the level of the upper limb, suggesting that acromegalic patients may have some degree of endothelial dysfunction. Elsewhere, studies involving hypopituitary GH-deficient adults have shown that GH and/or IGF-I may have direct effect on endothelial function. SUBJECTS AND METHODS: We thus compared cutaneous vasoreactivity responses in 10 normotensive patients with active acromegaly (A) (six women and four men) aged 25-59 (mean, 43.2 years), whose basal GH and IGF-I levels ranged from 7.4 to 158 mU/l and from 401 to 1690 microg/l, respectively, and in 10 normal age- and sex-matched controls (NC) by means of Laser Doppler flowmetry at the levels of the palm and the dorsum of the right hand. Circulatory skin velocities were studied basally and after increasing skin temperature to 44 degrees C (in order to study direct nonspecific vasodilatation response which is independent of endothelial or autonomous nervous system and reflects normal vascular muscle function), after shear-stress (known to produce flow-dependent vasodilatation, mediated by nitric oxyde (NO) originating from endothelial cells) and after cold-stress applied on the opposite hand (known to produce vaso-constriction mediated by the sympathetic nervous system).
RESULTS: The warm test induced a significant (P<0.001) and similar increase in both dorsal and palmar skin perfusion in A (mean +/- SD) (240+/-96 and 238+/-134%, respectively) and NC (232+/-137 and 233+/-73, respectively). Ischaemia release induced a significant increase in both dorsal and palmar skin blood flows in the two groups (P<0.001), but reactivities in acromegalic patients were about one half of those measured in controls (22.9+/-16.2% (A) vs. 46.9 25% (NC), 2P<0.02, at the level of the dorsum; and 45.0+/-43.6% (A) vs. 104.7+/-40.1 (NC), 2P<0.01, at the level of the palm). Cold pressor test resulted in significant decreases in both cutaneous flows (P<0.01) in the two groups, with a larger vasoconstriction (that did not reach statistical significance) in acromegalic patients as compared with controls (P< 0.10).
CONCLUSION: Vascular smooth cell ability to produce skin vasodilatation is normal but endothelium-dependent vasodilatation appears to be impaired while sympathetic-mediated vasoconstrictive response might be increased in acromegaly. This endothelial dysfunction may contribute to hypertension and represent a risk factor for cardiovascular complications in acromegaly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012569     DOI: 10.1046/j.1365-2265.2000.01127.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients.

Authors:  Xia Zhang; Jin Ma; Yuhan Wang; Lüe Li; Lu Gao; Xiaopeng Guo; Bing Xing; Yong Zhong
Journal:  Endocrine       Date:  2018-01-10       Impact factor: 3.633

2.  The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.

Authors:  M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

3.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 4.  Growth hormone, prolactin, and sexuality.

Authors:  M Galdiero; R Pivonello; L F S Grasso; A Cozzolino; A Colao
Journal:  J Endocrinol Invest       Date:  2012-09       Impact factor: 4.256

5.  N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly.

Authors:  S Arikan; M Bahceci; A Tuzcu; D Gokalp
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

6.  Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

Authors:  A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

7.  Left ventricular synchronicity is impaired in patients with active acromegaly.

Authors:  Abdulkadir Kırış; Cihangir Erem; Oğuzhan Ekrem Turan; Nadim Civan; Gülhanım Kırış; Irfan Nuhoğlu; Abdulselam Ilter; Halil Onder Ersöz; Merih Kutlu
Journal:  Endocrine       Date:  2012-12-20       Impact factor: 3.633

8.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

9.  Intracranial internal carotid artery changes in acromegaly: a quantitative magnetic resonance angiography study.

Authors:  Renzo Manara; Joseph Gabrieli; Valentina Citton; Filippo Ceccato; Silvia Rizzati; Giulia Bommarito; Chiara Briani; Alessandro Della Puppa; Francesca Dassie; Laura Milanese; Francesco Di Salle; Mario Ermani; Carla Scaroni; Chiara Martini; Pietro Maffei
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

10.  Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.

Authors:  Agatha A van der Klaauw; Jeroen J Bax; Ferdinand Roelfsema; Marcel P M Stokkel; Gabe B Bleeker; Nienke R Biermasz; Johannes W A Smit; Johannes A Romijn; Alberto M Pereira
Journal:  Pituitary       Date:  2009-06-12       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.